Climb Bio (CLYM) Non-Current Assets (2020 - 2026)
Climb Bio (CLYM) posted Non-Current Assets of $39.0 million for Q1 2026, down 37.04% on a QoQ basis from $61.9 million in Q4 2025, and down 61.21% year-over-year from $100.5 million in Q1 2025.
Climb Bio (CLYM) Non-Current Assets (2020 - 2026) Analysis & Trends
Climb Bio's Non-Current Assets history runs 7 years deep, the most recent figure standing at $39.0 million for Q1 2026.
- Quarterly Non-Current Assets fell 61.21% year-over-year to $39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297.2 million (up 58.61% YoY) and the FY2025 annual result came in at $61.9 million, down 0.67% from the prior year.
- Non-Current Assets was $39.0 million for Q1 2026 at Climb Bio, down from $61.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $105.0 million in Q2 2025 and bottomed at $21000.0 in Q2 2024.
- A 5-year average of $32.0 million and a median of $17.0 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets sank 98.97% — and 2025, when it surged 499909.52%.
- Climb Bio's Non-Current Assets stood at $599000.0 in 2022, then slumped by 64.27% to $214000.0 in 2023, then jumped by 29019.16% to $62.3 million in 2024, then fell by 0.67% to $61.9 million in 2025, then plunged by 37.04% to $39.0 million in 2026.
- Business Quant data shows CLYM's Non-Current Assets at $39.0 million in Q1 2026, $61.9 million in Q4 2025, and $91.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | 38.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.97 Mn |
| Dec 31, 2025 | 61.90 Mn |
| Sep 30, 2025 | 91.34 Mn |
| Jun 30, 2025 | 105.00 Mn |
| Mar 31, 2025 | 100.46 Mn |
| Dec 31, 2024 | 62.32 Mn |
| Sep 30, 2024 | 24.59 Mn |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Dec 31, 2023 | 214,000.00 |
| Sep 30, 2023 | 301,000.00 |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 1.91 Mn |
| Dec 31, 2022 | 599,000.00 |
| Sep 30, 2022 | 7.69 Mn |
| Jun 30, 2022 | 17.03 Mn |
| Mar 31, 2022 | 29.14 Mn |
| Dec 31, 2021 | 24.99 Mn |
| Sep 30, 2021 | 23.62 Mn |
| Jun 30, 2021 | 2.82 Mn |